Investigation Launched into ADC Therapeutics: Safety Concerns in LOTIS-7 Trial Draw Scrutiny

ADC Therapeutics (NYSE: ADCT) is now in the legal spotlight. Pomerantz LLP, a top law firm in securities class action litigation, has announced an investor-focused investigation into the company’s recent disclosures. The focus? Safety events reported in the highly anticipated LOTIS-7 Phase 1b trial for ZYNLONTA® combined with bispecific antibody glofitamab (COLUMVI®), targeting patients with aggressive diffuse large B-cell lymphoma (r/r DLBCL).

Key Trigger: Adverse Events Surface Despite Positive Clinical Framing

On December 3, 2025, ADC Therapeutics published what was positioned as an update with promising clinical data. But a closer look revealed that two patients experienced adverse events, with one seen as likely treatment-related. More significantly, cytokine release syndrome—a potentially dangerous immune reaction—was observed in 36.7% of participants across dose levels. While these risks can be expected in early-stage and combination cancer therapies, they nonetheless heightened investor anxieties around the drug’s safety profile.

Legal Response Driven by Potential Securities Fraud Risk

Pomerantz LLP’s investigation centers on whether ADC Therapeutics or its management may have engaged in securities fraud or unlawful business practices related to these disclosures. Investors are encouraged to contact the firm for more information about participating in a possible class action suit. Given the firm’s reputation for high-profile corporate litigation, the news adds a level of legal uncertainty just as the company is pushing its oncology pipeline forward.

Stock Reaction: Prior Decline Sets the Stage for Cautious Trading

ADC’s stock closed at $3.95 on December 3, 2025, down 14.13%, immediately after the clinical data went public. As of 11:10 AM today, shares trade at $3.57, reflecting a quieter, but persistent, wariness in the market as legal clouds form.

What’s Next? Investors Weigh Clinical Uncertainty Against Legal Risks

While Pomerantz’s investigation is in its early stages, it raises important questions about transparency in biotech disclosures—especially when clinical trials surface notable risks. Investors and followers of ADC Therapeutics should monitor both regulatory developments and the company’s updates on its oncology pipeline. With safety in the spotlight, the next steps could be pivotal for both shareholders and cancer patients alike.

Key Takeaway: Ongoing Litigation and Safety Concerns Add to ADC Therapeutics’ Uncertainty

With a premier litigation firm on the case and questions swirling around trial safety data, ADCT finds itself at a crossroads. The outcome of both the legal investigation and clinical follow-up data will likely drive the next chapter for this cancer therapy developer, and investors should keep a close eye on forthcoming disclosures.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI